Clene Inc. (CLNN)
Drugs • Health Care
July 29, 2026 Clene Inc. to Showcase Innovations at Canaccord 46th Annual Growth Conference Clene Inc. will participate in the Canaccord 46th Annual Growth Conference, presenting its advancements in neurodegenerative disease therapies. This event provides a crucial platform for investor engagement and highlights the company's commitment to innovative treatments.
May 14, 2026 Clene Inc. Reports First Quarter 2026 Financial Results and Operational Progress Clene Inc. announces promising Q1 2026 results, highlighting progress in ALS treatment with CNM-Au8 and a solid financial position. The company plans to submit an NDA in Q3 2026, supported by encouraging FDA discussions.
May 14, 2026 Clene Inc. Reports 2026 Q1 Financial Results: Navigating Challenges in Clinical Development Clene Inc. reports its Q1 2026 financial results, facing significant losses while advancing clinical trials for ALS and MS. The company anticipates submitting a key NDA and launching Phase 3 trials, despite financial challenges.
May 05, 2026 Clene Inc. to Showcase Innovative Research at Upcoming May Conferences Clene Inc. is set to present its innovative research on neurodegenerative diseases at two major investor conferences in May 2026. The company aims to transform treatment for conditions like ALS and MS with its pioneering therapies, including the investigational product CNM-Au8®. Investors can engage with Clene's advancements in virtual and in-person formats.
May 05, 2026 Clene Inc. Announces $7 Million Underwritten Offering of Common Stock Clene Inc. has announced a $7 million underwritten offering of common stock aimed at funding critical initiatives including NDA preparation for their lead drug CNM-Au8®. The proceeds will also support clinical trials, manufacturing expansion, and early-stage R&D efforts.
May 04, 2026 Clene Inc. Accelerates NDA Filing for ALS Drug Following FDA Meeting Clene Inc. has announced plans to file a New Drug Application for its ALS drug candidate CNM-Au8 following positive feedback from the FDA. The agency indicated that Clene's data could support accelerated approval, emphasizing the importance of neurofilament light chain as a potential surrogate endpoint. This milestone reflects Clene's commitment to addressing urgent needs in the ALS community.
March 17, 2026 Clene Inc. Reports Annual Financial Results for 2025: A Year of Challenges and Clinical Progress Clene Inc. released its 2025 annual report showcasing significant clinical progress in ALS and MS treatments, despite facing financial challenges and a net loss of $26.17 million. The company is focused on enhancing its clinical pipeline while navigating liquidity concerns and exploring funding options for future growth.
March 12, 2026 Clene Inc. Reports Strong Progress in Neurodegenerative Disease Trials and Financial Results for 2025 Clene Inc. has made significant strides in its clinical trials for neurodegenerative diseases, particularly ALS, with promising biomarker results for its treatment candidate CNM-Au8. The company also reports improved financial performance for 2025, indicating a focus on strategic growth and upcoming FDA engagements.
February 24, 2026 Clene Inc. Highlights Promising Milestones for CNM-Au8® in 2026 Clene Inc. outlined its 2026 milestones for CNM-Au8®, focusing on regulatory approvals and ongoing clinical trials for ALS and MS. With solid financial support and positive data, the company is committed to advancing neurodegenerative disease treatments.
February 19, 2026 Clene Inc. to Present at the Emerging Growth Conference Clene Inc. will present its corporate update at the Emerging Growth Conference on February 25, 2026, focusing on innovative treatments for neurodegenerative diseases. The event will highlight Clene's advancements in mitochondrial health and its flagship therapy, CNM-Au8®, aimed at enhancing CNS cell functionality.
January 16, 2026 Clene Inc. to Present at Emerging Growth Conference: A Focus on Neurodegenerative Disease Treatments Clene Inc. will present at the Emerging Growth Conference on January 21, 2026, focusing on its advancements in neurodegenerative disease treatments. The company aims to highlight its investigational therapy, CNM-Au8®, emphasizing its commitment to mitochondrial health and innovative solutions.
January 12, 2026 Clene Inc. Advances Towards FDA Review with Promising CNM-Au8 Biomarker Data Clene Inc. is preparing for a crucial FDA Type C meeting to discuss biomarker data supporting its ALS treatment, CNM-Au8. Recent findings on neurofilament light chain and IGFBP7 indicate potential survival benefits, raising hopes for accelerated approval.
January 09, 2026 Clene Inc. Announces Significant Registered Direct Offering of Over $28 Million Clene Inc. has successfully raised over $28 million through a registered direct offering to support its development of therapies for neurodegenerative diseases. The investment from top-tier investors underscores confidence in Clene's promising lead product, CNM-Au8, as it prepares for FDA submissions in 2026.
December 09, 2025 Clene Inc. Set to Present at Emerging Growth Conference Clene Inc. will present at the Emerging Growth Conference on December 10, 2025, showcasing its advancements in therapies for neurodegenerative diseases. The presentation will provide insights into Clene's strategic direction and innovative treatment approaches.
December 03, 2025 Clene Inc. Announces Promising ALS Biomarker Results, Paving the Way for Accelerated Approval of CNM-Au8® Clene Inc. has revealed encouraging biomarker results for its ALS therapy, CNM-Au8, showing significant reductions in key biomarkers and improved survival rates. These findings may lead to accelerated FDA approval and a promising future for ALS treatment.
December 02, 2025 Clene Inc. Announces Upcoming Update on CNM-Au8® ALS Program Clene Inc. will provide a significant update on its CNM-Au8® program for ALS during a conference call on December 3, 2025. This investigational therapy aims to improve mitochondrial health and neuronal function for those with neurodegenerative diseases.
November 20, 2025 Clene Inc. to Showcase Innovations at Benchmark 14th Annual Discovery Conference Clene Inc. is set to participate in the Benchmark 14th Annual Discovery Conference on December 4, 2025, in New York City. The event will allow Clene's management to connect with potential investors to discuss their advancements in treatments for neurodegenerative diseases such as ALS and MS.
November 13, 2025 Clene Inc. Reports Third Quarter 2025 Financial Results and Key Developments Clene Inc. reports a net loss of $8.8 million for Q3 2025, with significant developments in their ALS, MS, and PD treatment programs. The company anticipates key regulatory milestones ahead.
November 13, 2025 Clene Inc. Reports Q3 2025 Financial Results: A Comprehensive Look Clene Inc. reports a net loss of $16.9 million for Q3 2025 amid significant clinical advancements in treatments for ALS, MS, and PD. The company faces ongoing financial challenges as it seeks to secure funding and advance its clinical pipeline.
October 20, 2025 Clene Inc. to Showcase Innovations at Emerging Growth Conference Clene Inc. will showcase its advancements in treating neurodegenerative diseases at the Emerging Growth Conference on October 23, 2025. The virtual presentation will highlight their innovative therapy, CNM-Au8®, targeting mitochondrial function. Investors can join the live event or access a replay later.
October 15, 2025 Clene Inc. to Engage in Key Discussions at Maxim Growth Summit Clene Inc. will participate in the Maxim Growth Summit, focusing on neurodegenerative diseases and their innovative therapy, CNM-Au8®. The event includes a panel discussion and investor meetings, highlighting Clene's commitment to enhancing patient outcomes.
September 25, 2025 Clene Inc. Unveils Promising Clinical Data for CNM-Au8® at ECTRIMS 2025 Clene Inc. presented new clinical data for its MS therapy, CNM-Au8®, at ECTRIMS 2025. The study showed significant improvements in brain energy metabolism and safety, paving the way for future treatments.
August 14, 2025 Clene Inc. Reports Q2 2025 Results: Navigating Challenges in the Pharmaceutical Landscape Clene Inc. reported a net loss of $7.41 million for Q2 2025 amid ongoing investments in drug development for neurodegenerative diseases. Despite liquidity challenges, the company remains optimistic about upcoming FDA submissions and clinical trial progress.
May 07, 2025 Clene Inc. Reports Q1 2025 Financial Results: Navigating Challenges in Clinical Development Clene Inc. reported a net loss of $4.1 million for Q1 2025, showing improvement from last year. Despite financial challenges, the company is advancing its lead drug candidate CNM-Au8® towards a Phase 3 trial, aiming for innovative treatments for neurodegenerative diseases.
April 01, 2025 Clene Inc. Set to Showcase Innovations at the Jones Healthcare and Technology Innovation Conference Clene Inc. will present its innovative treatments for neurodegenerative diseases at the Jones Healthcare and Technology Innovation Conference. The company focuses on mitochondrial health and neuronal function, aiming to attract investment and enhance its market presence. A webcast will be available for those unable to attend in person.
March 24, 2025 Clene Inc. Reports Mixed Results in 2024 Annual Report: A Look at Challenges and Opportunities in the Pharmaceutical Sector Clene Inc. released its 2024 annual report, showcasing significant financial losses and strategic initiatives aimed at overcoming challenges in the pharmaceutical sector. The company is focused on advancing its CSN therapeutics while addressing cash flow concerns and seeking additional funding.
March 24, 2025 Clene Inc. Reports Full Year 2024 Financial Results and Strategic Developments Clene Inc. has reported its full year 2024 financial results, showcasing key advancements in its ALS treatment, CNM-Au8, and preparations for upcoming Phase 3 trials. The company’s strategic focus includes engaging with the FDA for accelerated approval pathways and improving patient outcomes in neurodegenerative diseases.
March 12, 2025 Clene Inc. Reports Promising ALS Survival Data with CNM-Au8® Treatment Clene Inc. announces groundbreaking survival benefits of its investigational drug CNM-Au8® for ALS patients, showing significant median survival improvements. The findings support the drug's potential in extending life for those with ALS and set the stage for a Phase 3 trial in 2025.
March 06, 2025 Clene Inc. Set to Participate in the 37th Annual Roth Conference Clene Inc. is set to participate in the 37th Annual Roth Conference on March 18, 2025, highlighting its advancements in treating neurodegenerative diseases. The company aims to connect with investors and showcase its innovative therapies, including the promising CNM-Au8® treatment.
February 25, 2025 Clene Inc. Partners with APST to Enhance ALS Research Through NfL Biomarker Analysis Clene Inc. has partnered with APST Research to analyze neurofilament light chain biomarkers for ALS treatment CNM-Au8®. Utilizing extensive patient data, they aim to support FDA approval processes while ensuring patient safety.
February 19, 2025 SWOT Analysis of Clene Inc. in 2025 This SWOT analysis of Clene Inc. examines the company's strengths in innovative technology and a robust patent portfolio, alongside weaknesses like lack of revenue and dependency on drug candidates. It highlights opportunities in the expanding CNS market and the threats posed by competition and regulatory challenges.
November 13, 2024 Clene Inc. Reports Q3 2024 Financial Results Amid Continued Strategic Development Clene Inc. reported a net loss of $7.98 million in Q3 2024 as it continues to invest in clinical trials for CNS disorders. Despite financial pressures, the company is preparing for key ALS and MS trials, signaling its commitment to innovation in therapeutics.
August 07, 2024 Clene Inc. Reports Q2 2024: A Financial Overview Amidst Clinical Advancements Clene Inc. reports a revenue decline to $0.2 million in Q2 2024, with significant operating losses of $7.4 million. Despite financial challenges, the company shows promise with advancements in clinical trials for its lead drug, CNM-Au8, and plans for future funding.
May 08, 2024 Clene Inc. Reports Q1 2024 Financials: A Mixed Bag Amid Ongoing Challenges Clene Inc. reported mixed financial results for Q1 2024, incurring a net loss of $11.1 million despite a reduction in cash burn. The company is focused on securing additional funding to advance its drug candidates, including CNM-Au8 for CNS disorders, amid ongoing challenges.